Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects

American Journal of Clinical Nutrition

Volumn 92, Issue 4, 2010, Pages 810-817

  Steinert, Robert E ^a   Poller, Birk ^a   Castelli, M Cristina ^b   Drewe, Juergen ^a   Beglinger, Christoph ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Emisphere Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; OCTANOIC ACID DERIVATIVE; PEPTIDE YY [3-36]; SODIUM N [8 (2 HYDROXYBENZOYL)AMINO]CAPRYLATE; UNCLASSIFIED DRUG; PEPTIDE YY; PEPTIDE YY (3 36); PLACEBO;

ADULT; ARTICLE; CALORIC INTAKE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MECHANISM; FEEDING BEHAVIOR; FOOD INTAKE; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EATING; ENERGY METABOLISM; HUNGER; ORAL DRUG ADMINISTRATION; REFERENCE VALUE; SATIETY;

ADMINISTRATION, ORAL; ADULT; DOUBLE-BLIND METHOD; EATING; ENERGY METABOLISM; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HUNGER; MALE; PEPTIDE YY; PLACEBOS; REFERENCE VALUES; SATIATION; YOUNG ADULT;

EID: 78049440734     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.2010.29663     Document Type: Article

References (30)

1. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008;32:1431-7.
2. Schwartz MW, Woods S, Porte DJ, Seeley R, Baskin D. Central nervous system control of food intake. Nature 2000;404:661-71.
3. Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005;129:1430-6.
4. Gutzwiller JP, Göke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999;44:81-6.
5. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39.
6. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996;271:E458-64.
7. Grandt D, Dahms P, Schimiczek M, Eysselein VE, Reeve JR Jr, Mentlein R. [Proteolytic processing by dipeptidyl aminopeptidase IV generates receptor selectivity for peptide YY (PYY).] Med Klin (Munich) 1993;88:143-5 (in German).
8. Beglinger C, Poller B, Arbit E, et al. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin Pharmacol Ther 2008;84:468-74.
9. Steinert RE, Poller B, Castelli MC, et al. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin Pharmacol Ther 2009;86(6):644-50.
10. Costill DL. Carbohydrates for exercise: dietary demands for optimal performance. Int J Sports Med 1988;9:1-18.
11. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord 2000;24:38-48.
12. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-20.
13. Verdich C, Flint A, Gutzwiller J, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382-9.
14. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650-4.
15. Zhang X, Shi T, Holmberg K, et al. Expression and regulation of the neuropeptide Y Y2 receptor in sensory and autonomic ganglia. Proc Natl Acad Sci USA 1997;94:729-34.
16. Nakagawa A, Satake H, Nakabayashi H, et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004;110:36-43.
17. Abbott CR, Monteiro M, Small CJ, et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 2005;1044:127-31.
18. Brownlees J, Williams CH. Peptidases, peptides and the mammalian blood-brain barrier. J Neurochem 1993;60:793-803.
19. Nonaka N, Shioda S, Niehoff M, Banks W. Characterization of blood-brain barrier permeability to PYY3-36 in the mouse. J Pharmacol Exp Ther 2003;306:948-53.
20. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007;117:13-23.
21. Yamamoto H, Lee C, Marcus J, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002;110:43-52.
22. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005;146:3748-56.
23. Lo CM, Zhang D, Pearson K, et al. Interaction of apolipoprotein AIV with cholecystokinin on the control of food intake. Am J Physiol Regul Integr Comp Physiol 2007;293:R1490-4.
24. Neary NM, Small C, Druce M, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005;146:5120-7.
25. Chen HC, Roth J, Schroeder B, Weyer C. Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy. Curr Diabetes Rev 2008;4:79-91.
26. Gutzwiller JP, Degen L, Matzinger D, Prestin S, Beglinger C. Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. Am J Physiol Regul Integr Comp Physiol 2004;287:R562-7.
27. Chelikani PK, Haver A, Reidelberger R. Ghrelin attenuates the inhibitory effects of glucagon-like peptide-1 and peptide YY(3-36) on food intake and gastric emptying in rats. Diabetes 2006;55:3038-46.
28. Sloth B, Holst J, Flint A, Gregersen N, Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 2007;292:E1062-8.
29. Schmitz O. The GLP-1 concept in the treatment of type 2 diabetes - still standing at the gate of dawn? J Clin Endocrinol Metab 2008;93:375-7.
30. MacLean CM, Casanova A, Baselgia-Jeker L, et al. Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. J Clin Pharmacol 2009;49:553-9.